A detailed history of Royal Bank Of Canada transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Royal Bank Of Canada holds 40,580 shares of AMRN stock, worth $20,290. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,580
Previous 40,865 0.7%
Holding current value
$20,290
Previous $28,000 10.71%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.57 - $0.8 $162 - $228
-285 Reduced 0.7%
40,580 $25,000
Q2 2024

Aug 14, 2024

SELL
$0.63 - $1.07 $12,447 - $21,141
-19,758 Reduced 32.59%
40,865 $28,000
Q1 2024

Nov 05, 2024

BUY
$0.82 - $1.35 $16,201 - $26,673
19,758 Added 48.35%
60,623 $53,000
Q4 2023

Feb 14, 2024

SELL
$0.66 - $0.91 $2,032 - $2,802
-3,080 Reduced 4.83%
60,623 $52,000
Q3 2023

Nov 14, 2023

BUY
$0.85 - $1.43 $2,125 - $3,575
2,500 Added 4.08%
63,703 $58,000
Q2 2023

Aug 14, 2023

SELL
$1.12 - $1.49 $2,240 - $2,980
-2,000 Reduced 3.16%
61,203 $72,000
Q1 2023

May 15, 2023

BUY
$1.19 - $2.19 $1,755 - $3,230
1,475 Added 2.39%
63,203 $94,000
Q4 2022

Feb 14, 2023

SELL
$1.07 - $1.34 $2,326 - $2,913
-2,174 Reduced 3.4%
61,728 $74,000
Q3 2022

Nov 14, 2022

BUY
$1.09 - $1.67 $1,466 - $2,246
1,345 Added 2.15%
63,902 $71,000
Q2 2022

Aug 15, 2022

SELL
$1.13 - $3.69 $1,045 - $3,413
-925 Reduced 1.46%
62,557 $93,000
Q1 2022

May 16, 2022

SELL
$2.85 - $3.73 $12,169 - $15,927
-4,270 Reduced 6.3%
63,482 $209,000
Q4 2021

Feb 14, 2022

SELL
$3.24 - $5.18 $12,474 - $19,943
-3,850 Reduced 5.38%
67,752 $228,000
Q3 2021

Nov 15, 2021

BUY
$3.94 - $5.84 $163,852 - $242,868
41,587 Added 138.55%
71,602 $365,000
Q2 2021

Aug 16, 2021

BUY
$4.26 - $6.5 $127,863 - $195,097
30,015 New
30,015 $132,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $202M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.